Start Date
September 30, 2022
Primary Completion Date
May 16, 2024
Study Completion Date
May 16, 2024
Oral Semaglutide
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Lead Sponsor
Novo Nordisk A/S
INDUSTRY